Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Randomized Placebo-controlled, Double-blind, Parallel Study to Assess the Safety and Efficacy of an Oral Marijuana-Based Investigational Medical Product to Treat Anxiety in Adults With Autism Spectrum Disorder (ASD)

NCT06526208 is registered in ClinicalTrials.gov with Southwest Autism Research & Resource Center as lead sponsor.

NCT NCT06526208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06526208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Randomized Placebo-controlled, Double-blind, Parallel Study to Assess the Safety and Efficacy of an Oral Marijuana-Based Investigational Medical Product to Treat Anxiety in Adults With Autism Spectrum Disorder (ASD)
Lead sponsor
Southwest Autism Research & Resource Center
Phase
Phase 2
Overall status
Recruiting
Start date
May 28, 2025
Completion date
September 30, 2027
Enrollment
108 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety, autism spectrum disorder